Dou, X., Zhong, Y., Zhao, W., Qin, L., Du, X., Liao, A., Xia, Z., Sun, C., Jiang, S., Huang, D., Xie, H., Ma, L., Wang, J., Jin, F., Ouyang, G., Tong, Y., Dong, M., Xu, B., He, W., Cai, S., Lu, J. (2025). A first-in-human, phase I/II, open-label, multicenter, dose escalation and expansion study of lbl-034, a conditionally activated bispecific antibody targeting GPRC5D and CD3 with a 2:1 format, in patients with relapsed/refractory multiple myeloma. Blood. https://doi.org/10.1182/blood-2025-91